Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
86.55 USD | -1.00% |
|
+2.22% | +5.90% |
Feb. 07 | Vaxcyte Insider Sold Shares Worth $450,369, According to a Recent SEC Filing | MT |
Feb. 05 | Vaxcyte Advances Phase 2 Study on Infant Pneumococcal Disease Prevention to Final Stage | MT |
Consensus | 4m Target Price Revision | 4m Revision of opinion | Divergence of analysts' opinions | Divergence of Target Price | Average Target P. | Ecart obj. / dr | Nbr of analysts | ||
---|---|---|---|---|---|---|---|---|---|
$149.89 | +71.46% | 9 | |||||||
$490.59 | +4.53% | 29 | |||||||
$939.37 | +32.31% | 25 | |||||||
€632.14 | +0.02% | 16 | |||||||
$134.36 | +18.53% | 20 | |||||||
$283.39 | +26.8% | 23 | |||||||
CN¥66.34 | +14.05% | 17 | |||||||
$26.81 | +64.23% | 7 | |||||||
$90.45 | +13.14% | 16 | |||||||
$168.64 | +37.53% | 24 | |||||||
DKK 2,292.13 | +65.5% | 16 | |||||||
HK$20.1 | +0.89% | 25 | |||||||
$184.91 | +65.36% | 20 | |||||||
$35.93 | +7.3% | 22 | |||||||
HK$71.34 | +18.02% | 18 | |||||||
$378.43 | +13.74% | 14 | |||||||
$186.1 | +59.75% | 15 | |||||||
DKK 1,007.64 | +38.32% | 11 | |||||||
NT$854.8 | +22.29% | 5 | |||||||
Average | 421.76 | +30.20% | 17 | ||||||
Weighted average by Cap. | 499.42 | +21.51% | 22 |
- Stock Market
- Equities
- PCVX Stock
- Sector Vaxcyte, Inc.
- Sector consensus